Zelluna TCR-NK Candidate (Platform-Optimized)

About Etcembly

Etcembly is an AI-native biotech developing a sophisticated platform, EMLy Co-pilot, to accelerate and de-risk the design of complex biologics such as monoclonal antibodies and T-cell receptors (TCRs). Founded by veterans with deep experience in developing FDA-approved therapies, the company differentiates itself by focusing on the critical developability and manufacturability constraints that often cause candidate failure. Operating as a private, platform-focused company, Etcembly serves both biotech partners and internal programs, with an early external validation point as a TCR-NK candidate optimized using its platform advances toward the clinic.

Therapeutic Areas